169 related articles for article (PubMed ID: 36515735)
1. Antipsychotics and risk of QT prolongation: a pharmacovigilance study.
Bordet C; Garcia P; Salvo F; Touafchia A; Galinier M; Sommet A; Montastruc F
Psychopharmacology (Berl); 2023 Jan; 240(1):199-202. PubMed ID: 36515735
[TBL] [Abstract][Full Text] [Related]
2. Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis.
Chung AK; Chua SE
J Psychopharmacol; 2011 May; 25(5):646-66. PubMed ID: 20826552
[TBL] [Abstract][Full Text] [Related]
3. Withdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022.
Storck W; de Laportalière TT; Yrondi A; Javelot H; Berna F; Montastruc F
Psychopharmacology (Berl); 2024 Jun; 241(6):1205-1212. PubMed ID: 38376511
[TBL] [Abstract][Full Text] [Related]
4. P-Glycoprotein-Mediated Interaction Is a Risk Factor for QT Prolongation in Concomitant Use of Antipsychotics and SSRIs as P-Glycoprotein-Mediated Inhibitors: Analysis of the Japanese Adverse Drug Event Report Database.
Morishita H; Perera LMB; Sunakawa H; Kimura S; Yoshida H; Ogihara T
J Clin Pharmacol; 2024 Jan; 64(1):118-124. PubMed ID: 37658631
[TBL] [Abstract][Full Text] [Related]
5. Linezolid and the risk of QT interval prolongation: A pharmacovigilance study of the Food and Drug Administration Adverse Event Reporting System.
Shao H; Shi D; Dai Y
Br J Clin Pharmacol; 2023 Apr; 89(4):1386-1392. PubMed ID: 36346345
[TBL] [Abstract][Full Text] [Related]
6. Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System.
Fusaroli M; Raschi E; Giunchi V; Menchetti M; Rimondini Giorgini R; De Ponti F; Poluzzi E
Int J Neuropsychopharmacol; 2022 Sep; 25(9):727-736. PubMed ID: 35639870
[TBL] [Abstract][Full Text] [Related]
7. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
[TBL] [Abstract][Full Text] [Related]
8. Possible Lurasidone-Associated Dose-Dependent QTc Prolongation in First-Episode Psychosis.
Naguy A; Al-Khadhari S; Pridmore S
Psychopharmacol Bull; 2022 Jun; 52(3):68-71. PubMed ID: 35815172
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.
Kongsamut S; Kang J; Chen XL; Roehr J; Rampe D
Eur J Pharmacol; 2002 Aug; 450(1):37-41. PubMed ID: 12176106
[TBL] [Abstract][Full Text] [Related]
10. Evidence for a crucial modulating role of the sodium channel in the QTc prolongation related to antipsychotics.
Silvestre JS; O'Neill MF; Prous JR
J Psychopharmacol; 2014 Apr; 28(4):329-40. PubMed ID: 24327451
[TBL] [Abstract][Full Text] [Related]
11. Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials.
Jensen KG; Juul K; Fink-Jensen A; Correll CU; Pagsberg AK
J Am Acad Child Adolesc Psychiatry; 2015 Jan; 54(1):25-36. PubMed ID: 25524787
[TBL] [Abstract][Full Text] [Related]
12. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data.
Camm AJ; Karayal ON; Meltzer H; Kolluri S; O'Gorman C; Miceli J; Tensfeldt T; Kane JM
CNS Drugs; 2012 Apr; 26(4):351-65. PubMed ID: 22452529
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
Haddad PM; Anderson IM
Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of QT prolongation with serotonin reuptake inhibitors.
Ojero-Senard A; Benevent J; Bondon-Guitton E; Durrieu G; Chebane L; Araujo M; Montastruc F; Montastruc JL
Psychopharmacology (Berl); 2017 Oct; 234(20):3075-3081. PubMed ID: 28770276
[TBL] [Abstract][Full Text] [Related]
15. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.
Hasnain M; Vieweg WV
CNS Drugs; 2014 Oct; 28(10):887-920. PubMed ID: 25168784
[TBL] [Abstract][Full Text] [Related]
16. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotics and obsessive-compulsive disorder/obsessive-compulsive symptoms: A pharmacovigilance study of the FDA adverse event reporting system.
Burk BG; DiGiacomo T; Polancich S; Pruett BS; Sivaraman S; Birur B
Acta Psychiatr Scand; 2023 Jul; 148(1):32-46. PubMed ID: 37194481
[TBL] [Abstract][Full Text] [Related]
18. Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case.
Meyer-Massetti C; Vaerini S; Rätz Bravo AE; Meier CR; Guglielmo BJ
Int J Clin Pharm; 2011 Oct; 33(5):806-14. PubMed ID: 21809143
[TBL] [Abstract][Full Text] [Related]
19. Ziprasidone in the management of schizophrenia : the QT interval issue in context.
Taylor D
CNS Drugs; 2003; 17(6):423-30. PubMed ID: 12697001
[TBL] [Abstract][Full Text] [Related]
20. Association of Oral Contraceptives With Drug-Induced QT Interval Prolongation in Healthy Nonmenopausal Women.
Salem JE; Dureau P; Bachelot A; Germain M; Voiriot P; Lebourgeois B; Trégouët DA; Hulot JS; Funck-Brentano C
JAMA Cardiol; 2018 Sep; 3(9):877-882. PubMed ID: 30073300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
